Immunic AG is a specialist in selective oral drugs in immunology and focused on developing novel oral therapies with best-in-class potential for chronic inflammatory and autoimmune diseases.
Immunic is based in the Munich biotech hub Martinsried, Germany, and has subsidiaries in Halle/Saale, Germany, and Melbourne, Australia. The company currently develops three products for the treatment of chronic inflammatory and autoimmune diseases including e.g. inflammatory bowel disease, multiple sclerosis and psoriasis. Immunic’s lead development program, IMU-838, is currently in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with additional phase 2 trials in Crohn’s disease and primary sclerosing cholangitis planned for 2019. IMU-935 is a best-in-class inverse agonist of the nuclear receptor RORγt and currently in preclinical development. IMU-856 is a newly developed and orally available small molecule aiming at a yet undisclosed target and currently in preclinical testing.